TY - JOUR
T1 - Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients
T2 - A 2-year study
AU - Derosa, G.
AU - D'Angelo, A.
AU - Mugellini, A.
AU - Pesce, R. M.
AU - Fogari, E.
AU - Maffioli, P.
PY - 2012/9
Y1 - 2012/9
N2 - Objective: To evaluate if there is a correlation between some new emerging biomarkers, such as lipoprotein(a) (Lp[a]), apo(a) isoform phenotyping, soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L), serum myeloperoxidase (MPO), and cardiovascular risk stratification. Research design and methods: Three hundred patients were enrolled in this open-label, casecontrol design trial: 156 hypertensive patients and 144 healthy subjects as control group. Hypertensive patients were treated according to the latest ESH/ESC guidelines, until the desirable goal of systolic blood pressure (SBP)
AB - Objective: To evaluate if there is a correlation between some new emerging biomarkers, such as lipoprotein(a) (Lp[a]), apo(a) isoform phenotyping, soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L), serum myeloperoxidase (MPO), and cardiovascular risk stratification. Research design and methods: Three hundred patients were enrolled in this open-label, casecontrol design trial: 156 hypertensive patients and 144 healthy subjects as control group. Hypertensive patients were treated according to the latest ESH/ESC guidelines, until the desirable goal of systolic blood pressure (SBP)
KW - Cardiovascular risk
KW - Hypertension
KW - Lipoprotein(a)
KW - Non-conventional biomarkers
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84866641326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866641326&partnerID=8YFLogxK
U2 - 10.1185/03007995.2012.717527
DO - 10.1185/03007995.2012.717527
M3 - Article
C2 - 22852869
AN - SCOPUS:84866641326
SN - 0300-7995
VL - 28
SP - 1435
EP - 1445
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 9
ER -